Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03208023 · ClinicalTrials.gov registry record · NA
RESIPI for Reducing Perioperative Major Adverse Cardiac Events
A NA study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 155
- Enrollment target
NCT03208023: Clinical Trial NA study, sponsored by Vanderbilt University Medical Center.
NCT03208023 is a NA study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 155 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03208023, a NA study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 155 participants
- Enrollment target
Study Summary
This study aims to evaluate the effect of a novel hemodynamic management and monitoring strategy for reducing cardiac bio marker elevations and major adverse cardiac events.
Primary Outcome
Change in BNP (\>250 ng/ml)
Interventions
- OTHER No intervention
- PROCEDURE RESIPI Management Strategy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2017-10-09 |
| Est. Completion | 2018-12-03 |
| Phase | NA |
Why NCT03208023 stopped before completion
NCT03208023 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which No intervention is the first listed.
NCT03208023 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03208023 about?
NCT03208023 is a clinical study titled "RESIPI for Reducing Perioperative Major Adverse Cardiac Events". This study aims to evaluate the effect of a novel hemodynamic management and monitoring strategy for reducing cardiac bio marker elevations and major adverse cardiac events.
What is the current status of trial NCT03208023?
This trial is currently terminated. It is a NA study. The enrollment target is 155 participants. The study started on 2017-10-09. Estimated completion is 2018-12-03.
What interventions are being tested in trial NCT03208023?
The interventions under investigation include: No intervention (OTHER), RESIPI Management Strategy (PROCEDURE).
Who is sponsoring clinical trial NCT03208023?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03208023's enrollment target sits among peer trials
155 656th of 2000 higher than 1,345 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI